|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global Cancer Statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Saxena N, Lahiri SS, Hambarde S and
Tripathi RP: RAS: target for cancer therapy. Cancer Invest.
26:948–955. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boguski MS and McCormick F: Proteins
regulating Ras and its relatives. Nature. 366:643–654. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bos JL: ras oncogenes in human
cancer: a review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
|
|
5
|
Bollag G and McCormick F: Regulators and
effectors of ras proteins. Annu Rev Cell Biol. 7:601–632.
1991. View Article : Google Scholar
|
|
6
|
Sui G, Ma X, Liu S, Niu H and Dong Q:
Study of the correlation between H-ras mutation and primary
hepatocellular carcinoma. Oncol Lett. 4:779–782. 2012.PubMed/NCBI
|
|
7
|
Lim KH and Counter CM: Reduction in the
requirement of oncogenic Ras signaling to activation of PI3K/AKT
pathway during tumor maintenance. Cancer Cell. 8:381–392. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rotblat B, Ehrlich M, Haklai R and Kloog
Y: The Ras inhibitor farnesylthiosalicylic acid (Salirasib)
disrupts the spatiotemporal localization of active Ras: a potential
treatment for cancer. Methods Enzymol. 439:467–489. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reuter C, Morgan M and Bergmann L:
Targeting the Ras signaling pathway: a rational, mechanism-based
treatment for hematologic malignancies? Blood. 96:1655–1669.
2000.PubMed/NCBI
|
|
10
|
Méndez-Sánchez N, Vásquez-Fernández F,
Zamora-Valdés D and Uribe M: Sorafenib, a systemic therapy for
hepatocellular carcinoma. Ann Hepatol. 7:46–51. 2008.PubMed/NCBI
|
|
11
|
Njoroge FG, Doll RJ, Vibulbhan B, et al:
Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl
protein transferase. Bioorg Med Chem. 5:101–113. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang G, Thompson JA, Fang B and Liu J:
Silencing of H-ras gene expression by retrovirus-mediated
siRNA decreases transformation efficiency and tumor growth in a
model of human ovarian cancer. Oncogene. 22:5694–5701. 2003.
|
|
13
|
Hansen MB, Nielsen SE and Berg K:
Re-examination and further development of a precise and rapid dye
method for measuring cell growth/cell kill. J Immunol Methods.
119:203–210. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paoluzzi L, Gonen M, Bhagat G, et al: The
BH3-only mimetic ABT-737 synergizes the antineoplastic activity of
proteasome inhibitors in lymphoid malignancies. Blood.
112:2906–2916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Rayburn ER, Wang W, Kandimalla ER,
Agrawal S and Zhang R: Chemotherapy and chemosensitization of
non-small cell lung cancer with a novel immunomodulatory
oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther.
5:1585–1592. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sepp-Lorenzino L, Rands E, Mao X, et al: A
novel orally bioavailable inhibitor of kinase insert
domain-containing receptor induces antiangiogenic effects and
prevents tumor growth in vivo. Cancer Res. 64:751–756. 2004.
View Article : Google Scholar
|
|
17
|
Crowder C, Kopantzev E, Williams K, Lengel
C, Miki T and Rudikoff S: An unusual H-Ras mutant isolated from a
human multiple myeloma line leads to transformation and
factor-independent cell growth. Oncogene. 22:649–659. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnston SR: Farnesyl transferase
inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol.
2:18–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang Z, Qin L, Wang X, et al: Alterations
of oncogenes, tumor suppressor genes and growth factors in
hepatocellular carcinoma: with relation to tumor size and
invasiveness. Chin Med J. 111:313–318. 1998.PubMed/NCBI
|
|
20
|
Iida M, Iwata H, Inoue H, Enomoto M, Horie
N and Takeishi K: Correlation between Bcl-2 overexpression and
H-ras mutation in naturally occurring hepatocellular
proliferative lesions of the B6C3F1 mouse. Toxicol Sci. 56:297–302.
2000.
|
|
21
|
Fleming JB, Shen GL, Holloway SE, Davis M
and Brekken RA: Molecular consequences of silencing mutant
K-ras in pancreatic cancer cells: justification for
K-ras-directed therapy. Mol Cancer Res. 3:413–423.
2005.PubMed/NCBI
|
|
22
|
Adjei AA: Blocking oncogenic Ras signaling
for cancer therapy. J Natl Cancer Inst. 93:1062–1074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Friday BB and Adjei AA: Advances in
targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase
cascade with MEK inhibitors for cancer therapy. Clin Cancer Res.
14:342–346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and
subcellular localization. Genes Dev. 12:3499–3511. 1998.
|
|
26
|
Gesbert F, Sellers WR, Signoretti S, Loda
M and Griffin JD: BCR/ABL regulates expression of the
cyclin-dependent kinase inhibitor p27Kip1 through the
phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem.
275:39223–39230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pugazhenthi S, Nesterova A, Sable C, et
al: Akt/protein kinase B up-regulates Bcl-2 expression through
cAMP-response element-binding protein. J Biol Chem.
275:10761–10766. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bernhard EJ: Pancreatic cancer inhibition
by specific knockdown of K-ras mutant allele expression. Cancer
Biol Ther. 6:293–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ming L, Wang P, Bank A, Yu J and Zhang L:
PUMA dissociates Bax and Bcl-XL to induce apoptosis in
colon cancer cells. J Biol Chem. 281:16034–16042. 2006.PubMed/NCBI
|
|
30
|
Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang
L and Dong Z: Regulation of PUMA-α by p53 in
cisplatin-induced renal cell apoptosis. Oncogene. 25:4056–4066.
2006.
|
|
31
|
Hemann MT, Zilfou JT, Zhao Z, Burgess DJ,
Hannon GJ and Lowe SW: Suppression of tumorigenesis by the p53
target PUMA. Proc Natl Acad Sci USA. 101:9333–9338. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Villunger A, Michalak EM, Coultas L, et
al: p53- and drug-induced apoptotic responses mediated by BH3-only
proteins puma and noxa. Science. 302:1036–1038. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsuruya K, Yotsueda H, Ikeda H, et al:
Involvement of p53-transactivated Puma in cisplatin-induced renal
tubular cell death. Life Sci. 83:550–556. 2008. View Article : Google Scholar : PubMed/NCBI
|
